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Background: Despite recommended pharmacotherapies the use of secondary prevention therapy after myocardial
infarction (MI) remains suboptimal. Patients with diabetes mellitus (DM) have worse prognosis after MI compared to
patients without DM and aggressive secondary prevention pharmacotherapy in this population is therefore
warranted. We examined the changes in use of evidence-based secondary prevention pharmacotherapy in patients
with and without DM discharged after first MI.
Methods: All patients aged 30 years or older admitted with first MI in Denmark during 1997–2006 were identified by
individual-level linkage of nationwide registries of hospitalizations. Univariate and multivariate logistic regression models
were used to identify patient characteristics associated with initiation of acetylsalicylic acid, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, β-blockers, and clopidogrel within 90 days, and statins within 180
days of discharge, respectively.
Results: A total of 78,230 patients were included, the mean age was 68.3 years (SD 13.0), 63.5% were men and 9,797
(12.5%) had diabetes. Comparison of claimed prescriptions in the period 1997–2002 and 2003–2006 showed significant
(p < 0.001) increases in claims for acetylsalicylic acid (38.9% vs. 69.7%), angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers (38.7% vs. 50.4%), β-blockers (69.2% vs. 77.9%), clopidogrel (16.7% vs. 66.3%), and statins
(41.3% vs. 77.3%). During 2003–2006, patients with DM claimed significantly less acetylsalicylic acid (odds ratio [OR] 0.81
[95% confidence interval [CI] 0.74–0.88) and clopidogrel (OR 0.91 [95% CI 0.83–1.00]) than patients without DM.
Conclusions: Despite sizeable increase in use of evidence-based secondary prevention pharmacotherapy after MI
from 1997 to 2006, these drugs are not used in a substantial proportion of subjects and patients with DM received
significantly less antiplatelet therapy than patients without DM. Increased focus on initiation of secondary prevention
pharmacotherapy after MI is warranted, especially in patients with DM.Background
Optimal use of evidence-based secondary prevention
pharmacotherapy in patients with myocardial infarction
(MI) reduces the risk of subsequent cardiovascular
events and mortality [1-5]. The internationally recom-
mended pharmacotherapies based on confirmative trials
for secondary prevention after MI during the study
period 1997–2006 included treatment with platelet in-
hibitors (acetylsalicylic acid [ASA] and a thienopyridine,* Correspondence: casperj@dadlnet.dk
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article, unless otherwise stated.e.g. clopidogrel), β-blockers, and lipid-lowering agents
for most patients without contraindications and irre-
spective of reperfusion therapy [6-12]. Furthermore,
high-risk post-MI patients with diabetes mellitus (DM),
clinical heart failure, and/or left ventricular dysfunction
should additionally receive angiotensin-converting en-
zyme inhibitors/angiotensin 2 receptor blockers (ACEIs/
ARBs) [5,13].
Patients with DM have worse prognosis after MI
compared to patients without DM and aggressive
secondary prevention pharmacotherapy is warranted in
DM patients [14]. Despite substantial data, however, the
use of secondary prevention therapy after MI remainstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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portant topic, the current study used population-based
administrative databases to examine the temporal devel-
opment in use of evidence-based secondary prevention
pharmacotherapy in post-MI patients, with particular
focus on patients with DM.
Methods
Health care system in Denmark
All permanent residents in Denmark can use the Danish
health care system freely and are entitled to free treat-
ment at a hospital. Data in the present study were ob-
tained from admissions all of 82 existing public hospitals
in Denmark in 1996. Expenses for the cost of drugs are
partially reimbursed. The more expenses patients have
for reimbursable drugs, the more reimbursement they
will receive. Annual medical expenses >900 Danish
Kroners (DKr) are reimbursed by 50%, >1,470 DKr by
75%, and >3,180 DKr by 85%. Moreover, general practi-
tioners can apply (usually successfully) for 100% reim-
bursement of drug expenses payable to their patients
with chronic conditions, i.e. DM.
Databases
In Denmark all citizens have a unique personal civil
registration number, allowing individual linkage of infor-
mation across nationwide registers. The Danish National
Patient Register holds information of all admissions and
invasive therapeutic procedures performed in Danish
hospitals since 1978. Each admission is registered by one
primary diagnosis and, if appropriate, one or more sec-
ondary diagnoses, coded according to the 8th or 10th re-
vision of the International Classification of Diseases
(ICD-8 code 410 for 1978–94 and ICD-10 codes I21–I22
from 1995 and onwards). The diagnosis of MI has previ-
ously been validated in the National Patient Registry
with a specificity of 93% [16]. The Danish Register
of Medicinal Product Statistics (National Prescription
Register) holds information on all prescriptions dis-
pensed from Danish pharmacies since 1995. Drugs are
registered according to the international Anatomical
Therapeutical Chemical (ATC) classification system. The
national health care reimbursement scheme of drug ex-
penses requires pharmacies in Denmark to register all
dispensed prescriptions, which ensures complete regis-
tration [17]. Percutaneous coronary interventions (PCI)
and coronary by-pass grafting (CABG) procedures per-
formed <30 days after admission were detected by use of
the Danish Health Care Classification System using the
codes KFNG and KNFA-KNFE, respectively.
Study population
Patients aged ≥30 years admitted to Danish hospitals
during 1997–2006 with a diagnosis of first MI (ICD-10codes I21–I22) were identified from the Danish National
Patient Registry. To certify the first hospitalization for
MI, we traced the hospitalizations of all patients back to
1978. Patients with DM were identified in the Danish
Register of Medicinal Product Statistics as individuals
claiming at least one prescription for glucose-lowering
drugs (GLDs; ATC A10), including all oral agents and
insulin, in the period from 180 days before to 90 days
after admission for MI. Although use of GLDs repre-
sents a conservative approach to identification of DM,
this strategy has been shown to capture at least 85% of
patients with DM in Denmark and it has a positive pre-
dictive value of 98% [18]. In 2002 the treatment strategy
for ST-segment elevation myocardial infarction (STEMI)
in Denmark was changed from fibrinolysis to primary PCI
after results of the DANAMI II trial were presented [19].
Based on these treatment changes in 2002, we therefore
specifically compared patients with first MI in the period
1997–2002 with patients admitted in 2003–2006.
Pharmacotherapy
We identified secondary prevention pharmacotherapy
prescriptions claimed ≤90 days of discharge after first
MI. The following drugs (ATC codes) were identified:
ASA (B01AC06), ACEIs/ARBs (C09), β-blockers (C07),
clopidogrel (B01AC04), and statins (A10A). Initiation of
statin treatment has been shown to increase during the
first 6 months after discharge after MI [20] and therefore
prescription claims within the first 180 days after dis-
charge were selected to identify patients that initiated
statin therapy. Initiation of β-blockers and ACEIs/ARBs
has been shown to occur primarily during the first 30
days after MI [20]. In addition, claims of loop-diuretics
(C03C) and proton pump inhibitors (PPIs; A02B) were
identified as proxies for heart failure (HF) and dyspeptic
disease, respectively.
Comorbidity
Comorbidity was defined according to the modified
Ontario Myocardial Infarction Mortality Prediction Rules
by admission diagnoses at the index admission and 1 year
previously [21]. The following diagnoses (ICD-10 codes)
were used: HF (I42, I43, I50) cardiac dysrhythmias
(I47-I49), pulmonary edema (J81), shock (R57), cerebro-
vascular disease (I60-I69), DM with chronic complications
(E10-E14), acute renal failure (N17, N19, R34), chronic
renal failure (N18, I12, I13) and malignancy (C00-C97).
Statistical analyses
All continuous variables were described as mean values ±
SD. Comparisons between groups were made using un-
paired t-test and χ2 test for discrete variables. Multivari-
able logistic regression models were used to analyze
differences in odds ratios (ORs) for drug use between
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patient age groups and between the two study periods,
respectively. Patients were stratified in 5 age groups, i.e.,
30–49 years, 50–59 years, 60–69 years, 70–79 years, and
≥80 years, and in age-dependent analyses, patients aged
60–69 years were chosen as the reference. Analyses were
adjusted for comorbidity and concomitant pharmacother-
apy. The linearity of continuous variables and lack of in-
teractions was tested and found valid unless otherwise
reported. Statistical calculations were performed with the
SAS statistical software package, version 9.1 (SAS Institute
Inc., Cary, NC).Figure 1 The selection of patients aged ≥30 years and alive 30Ethics
The Danish Data Protection Agency approved the study
(No. 2007-41-1667). Data were delivered with anon-
ymized, unique personal identification numbers, enabling
linkage between registers on an individual level. Retro-
spective register studies where individuals cannot be iden-
tified do not require ethical approval in Denmark [22].days after first myocardial infarction admitted to a Danish
hospital during 1 January 1997–31 December 2006.Results
During the 10-year study period, 101,852 patients with
MI were identified. Of these, 78,230 patients ≥30 years
of age alive 30 days after discharge after their first MI
were included in the study. The selection of the study
population is shown in Figure 1. The study population
comprised 49,665 (63.5%) men with a mean age of
65.7 years (SD 12.6), and 9,797 (12.5%) that claimed
GLDs in the period 180 days before or 90 days after the
index admission were identified as the study DM popu-
lation. The prevalence of DM increased from 12.1% in
1997–2002 to 13.1% in 2003–2006. During the 30 to 90
days after discharge 3,951 (5.1%) died of which 628
(15.9%) had DM, leaving 74,279 patients to claim drug
prescriptions for the entire period after discharge. For
the entire period, patients with DM accounted for 12.3%
of those surviving ≥ 90days. Patients with DM were
older, i.e., 69.2 (SD 11.8) years vs. 68.1 (SD 13.2) years,
more often women (39.4% vs. 36.1%; p < 0.0001) and had
more comorbidity at baseline, especially HF (27.5% vs.
17.4%; p < 0.0001), cardiac dysrhythmias (11.1% vs.
10.2%; p < 0.0001), and cerebrovascular disease (7.2%
vs. 4.4%; p < 0.0001), compared to patients without DM.
The use of loop diuretics (a proxy for HF) in the late
study period was significantly higher in DM patients
than in patients without DM (52.7% vs. 32.4%;
p < 0.0001). Women claimed more loop diuretics (OR
1.19 [95% CI 1.15-1.21]) than men. These findings were
consistent for both study periods (1997–2002 and
2003–2006) and were independent of DM status. Base-
line characteristics of the study population with and
without DM are shown in Table 1.Initiation of secondary prevention pharmacotherapy
The proportion of patients that claimed secondary pre-
vention therapy increased significantly over time, i.e., for
patients with DM the following increase in drug use be-
tween 1997–2002 and 2003–2006 was observed: ASA
from 37.4% to 64.3%, ACEIs/ARBs from 55.1% to 66.3%,
β-blockers from 64.8% to 75.8%, clopidogrel from 14.1%
to 62.2%, and statins from 39.1% to 77.5% (all p<0.0001).
Similarly for patients without DM drug use increased as
follows: ASA from 39.1% to 70.5%, ACEIs/ARBs from
36.4% to 48.0%, β-blockers from 69.8% to 78.2%, clopi-
dogrel from 17.0% to 69.9%, and statins from 41.6% to
77.3% (all p < 0.001). During the entire study period
1997–2006 patients with DM claimed significantly less
evidence-based secondary prevention pharmacotherapy
compared with patients without DM, except for ACEIs/
ARBs and statins in the late (2003–2006) study period.
An unadjusted analysis showed that the ORs for receiv-
ing ASA, β-blockers, and clopidogrel were significantly
lower in patients with DM compared to patients without
DM, while OR for treatment with ACEIs/ARBs was in-
creased in patients with DM (Table 2). Figure 2 shows
multivariable logistic regression analyses with ORs for
claims of secondary prevention pharmacotherapy in the
period 2003–2006 after adjustments for age, gender, and
comorbidity. In 2003–2006 patients with DM claimed
less ASA (OR 0.81 [95% CI 0.74-0.88]) and clopidogrel
(OR 0.91 [95% CI 0.83-1.00]) than patients without DM
(Figure 2). Sensitivity analyses excluding patients with
vs. without DM claiming ASA (26.5% vs. 15.0%) and
Table 1 Baseline characteristics
No DM DM p-value
Number: 68,433 9,797
Percentage of study population: 87.5 12.5
Gender, female (%) 36.1 39.4 <0.0001
Age at hospitalization (years ± SD ) 68.1 (±13.2) 69.2 (±11.8) <0.0001






ASA 39.1 37.4 <0.0149
ACEIs/ARBs 36.4 55.1 <0.0001
β-blockers 69.8 64.8 <0.0001
Clopidogrel 17.0 14.1 <0.0001




ASA 70.5 64.3 <0.0001
ACEIs/ARBs 48.0 66.3 <0.0001
β-blockers 78.2 75.8 <0.0005
Clopidogrel 66.9 62.2 <0.0001
Statins 77.3 77.5 0.8050
Comorbidity diseases (%)
Cardiac dysrhythmias 10.2 11.1 <0.0038
Heart failure 17.4 27.5 <0.0001
Pulmonary edema 1.0 1.8 <0.0001
Shock 0.9 1.5 <0.0001
Cerebrovascular disease 4.4 7.2 <0.0001
Renal disease 1.5 3.5 <0.0001
Diabetes complications 0.5 33.1 <0.0001
Malignancy 0.5 0.5 0.2953
Concomitant pharmacotherapy
Loop diuretics 35.1 54.4 <0.0001
Proton pump inhibitors 18.1 21.2 <0.0001
Reperfusion therapy
Percutaneous coronary intervention 28.0 21.8 <0.0001
Coronary artery by-pass graft 4.8 5.9 <0.0001
DM: diabetes mellitus, SD: standard deviation, ASA: acetyl salicylic acid, ACEI:
angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker,
CI: confidence interval.
Table 2 Univariate analysis
OR 95% CI p
ASA 0.75 0.70–0.81 <0.0001
ACEIs/ARBs 2.13 1.99–2.28 <0.0001
β-blockers 0.87 0.80–0.94 <0.0001
Statins 1.01 0.93–1.09 0.8054
Clopidogrel 0.81 0.76–0.87 <0.0001
Odds ratio (OR) for claiming secondary prevention pharmacotherapy after first
myocardial infarction during 2003–2006 in patients with vs. without diabetes
mellitus. ASA: acetyl salicylic acid, ACEI: angiotensin-converting enzyme inhibi-
tor, ARB: angiotensin receptor blocker, CI: confidence interval.
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provided similar results and in this analysis patients with
DM claimed less ASA (OR 0.76 [95% CI 0.69-0.84])
and clopidogrel (OR 0.90 [95% CI 0.82-0.98]) than
patients without DM. Statistically significant interactions
were found between all examined secondary prevention
pharmacotherapy agents and patient gender and age.The ORs for claiming secondary prevention therapy
were found to be significantly lower in women than in
men for β-blockers (OR 0.84 [95% CI 0.79–0.89]),
clopidogrel (OR 0.84 [95% CI 0.80–0.89]), and statins
(OR 0.79 [95% CI 0.74–0.84]). The proportion of
patients that claimed secondary prevention therapy
decreased significantly with increasing age, except for
claims of ASA, and this age-dependent decrease in
secondary prevention therapy was most apparent for
β-blockers and statins, i.e., patients aged >69 years had
OR 0.86 (95% CI 0.79–0.93) for receiving β-blockers and
OR 0.63 (95% CI 0.57–0.70) for receiving statins,
compared to patients aged 60–69 years, respectively.
Furthermore, as shown in Table 1, patients with DM
underwent significantly fewer PCI procedures and sig-
nificantly more CABG procedures (both p < 0.0001).
Combinations of secondary prevention pharmacotherapy
agents
The ORs for claiming two or more secondary prevention
drugs increased markedly between the two study pe-
riods. In the total study population the proportion of
patients claiming a combination of 2, 3, 4 and 5 agents
increased from 62.3% to 87.9%, 34.4% to 75.1%, 12.9% to
57.1% and 2.8% to 22.6 respectively, between 1997–2002
and 2003–2006. Patients with DM claimed more ACEIs/
ARBs in any combination than patients without DM.
A comparison of the use combinations of 2, 3, 4 and
5 agents, for patients with and without DM during
2003–2006, is shown in Figure 3.
Discussion
In this nationwide study of patients discharged after their
first MI in Denmark, we found that the proportion of
patients that claimed secondary prevention pharmacother-
apies increased substantially from 1997–2002 to 2003–
2006. Patients with DM, however, claimed less ASA and
clopidogrel than patients without DM, and women and the
elderly generally received less secondary prevention agents.
In the total study population, the fraction of patients claim-
ing a combination of two or more secondary prevention
pharmacotherapy agents increased significantly during the
Figure 2 Multivariable logistic regression analyses showing odds ratios for claiming secondary prevention therapy after first myocardial
infarction during 2003–2006 for acetylsalicylic acid (ASA), angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers
(ACEIs/ARBs), β-blockers, clopidogrel, and statins. DM: diabetes mellitus. Analyses were adjusted for age, gender, comorbidity, and concomitant
pharmacotherapy.
Jørgensen et al. BMC Cardiovascular Disorders 2014, 14:4 Page 5 of 9
http://www.biomedcentral.com/1471-2261/14/4study period but combination therapies appear to remain
underused as compared to treatment guidelines [2,3,23].
Although previous studies have shown that even in the
modern era patients with coronary artery disease generally
receive suboptimal secondary prevention pharmacotherapy
[15,24], our study adds important information on treat-
ment differences between patients with and without DM,
genders, and age groups, respectively, in an unselected
nationwide post-MI population. Specifically, the data
suggest that in post-MI patients with DM, there should be
increased focus on increased provision of antiplatelet ther-
apy with ASA and clopidogrel and of combinations of
evidence-based secondary prevention drug therapies. In
the general population, there also remains considerable
room for improvement of secondary prevention pharmaco-
therapy, particularly in women and the elderly.Antiplatelets
Platelet inhibitors, i.e., low dose ASA and clopidogrel are
recommended for secondary prevention after MI irre-
spective of, for example, patient gender, age, and DM
status [25-27]. In the current study, post MI patients
with DM claimed significantly less ASA and clopidogrel
than patients without DM. The reasons for this under-
treatment are not readily apparent but patients with
DM underwent more CABG than patients without DM
(Table 1), and contrary to treatment guidelines, surgeons
may discontinue clopidogrel after CABG in post MI pa-
tients [28]. Patients ≥70 years of age claimed signifi-
cantly less clopidogrel than the younger population,
whereas the use of ASA was not affected by increasing
age. Results from the Can Rapid risk stratification of
Unstable angina patients Suppress ADverse outcomes
Figure 3 Use of secondary prevention drugs after first
myocardial infarction in combinations of two, three, four or
five agents including acetylsalicylic acid, angiotensin-converting
enzyme inhibitors or angiotensin-2 receptor blockers, β-blockers,
clopidogrel, and statins, respectively, claimed ≤90 days after
discharge during the period 2003–2006. DM: diabetes mellitus.
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Cardiology/American Heart Association Guidelines
(CRUSADE) initiative have showed that even very old
(≥90 years) patients with acute coronary syndromes
benefit from clopidogrel treatment [29]. Consistent with
our findings, the use of ASA in patients with athero-
thrombotic disease was recently found to be lower in pa-
tients with DM than patients without DM in the
international Reduction of Atherothrombosis for Con-
tinued Health (REACH) registry [30]. Patients with DM
may have received less ASA due to clinicians’ concern of
retinal bleeding in patients with retinopathy. However,
the Early Treatment Diabetic Retinopathy Study Report
14 results from 1992 support treatment with ASA in pa-
tients with diabetes at increased risk of cardiovascular
disease and found no increased risk of retinal bleeding
associated with the use [6]. Female gender has previously
been associated with lower use of ASA [29], but in or
study there were no significant differences in claims of
ASA prescriptions between women and men. Unsurpris-
ingly, we found that a greater proportion of patients with
DM compared to patients without DM claimed ASA
and clopidogrel prior to admission, probably reflecting,
in part, the increased baseline rate of cerebrovascular
disease. The possibility that decreased utilization of ASA
and clopidogrel after first MI in patients with DM was
caused by these patients using their remaining stocks of
the antiplatelet agents after discharge was not supported
by our comparable finding in a sensitivity analysis that
excluded patients with prior use of ASA and clopidogrel.
Patients with DM have increased prevalence of gastro-
intestinal discomfort, e.g., due to gastroparesis, which
may reduce initiation of and compliance with pharmaco-
logic treatment, especially ASA and clopidogrel [31].After including claims of PPIs 90 days after discharge in
the multivariable analyses, however, there remained a
significant underuse in DM compared to non-DM pa-
tients. Mortality rates 30–90 days after MI, i.e., the
period where prescription claims were retrieved accord-
ing to our study design, did not differ significantly be-
tween patients with and without DM and are therefore
unlikely to have contributed to the observed discrepancy
in drug use between the two groups.
β-blockers
Secondary prevention with β-blockers after MI are rec-
ommended for all patients and is particularly important
because immediate treatment can reduce mortality and
risk of re-MI [2]. The absolute benefit of a given relative
reduction of post-MI risk may be greater in patients with
DM because of their higher absolute risk. In the current
study, the univariate analysis demonstrated a signifi-
cantly lower β-blocker use in DM patients (Table 2) and
the multivariate analysis (Figure 2) showed a similar
trend. Since β-blockers are also a mainstay in treatment
of severe HF, this apparent under treatment is reinforced
by the increased prevalence of HF in DM patients after
MI during the late (2003–2006) study period. Among
the reasons contributing to this finding may be the
widespread misconception that β-blockers may mask
symptoms of hypoglycemia and prolong recovery from
hypoglycaemia [32], although the value of β-blocker is
post MI DM patients has been firmly established [33].
Also, patients with DM in our study were slightly older
than their non DM controls and the elderly are at an in-
creased risk of adverse cardiac effects of β-blockers, e.g.,
low cardiac output and bradycardia, which together with
their increased prevalence of chronic obstructive lung
disease may have added to the underuse of β-blockers in
patients with DM.
Angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers
The international guidelines generally recommend ACEI/
ARB for secondary post MI prevention in patients with
HF, left ventricular ejection fraction less than 45%, DM,
hypertension, chronic renal disease, peripheral arterial
disease, and/or when patients are otherwise considered as
being at high risk [34,35]. In the current study, 50.4% of
patients claimed ACEIs/ARBs, which is markedly lower
than reported in the European Action on Secondary and
Primary Prevention through Interventions to Reduce
Events (EUROASPIRE) III survey where 71% reported use
of these agents six months after an acute coronary syn-
drome [24]. Patients included in that study, however, were
not exclusively those with first-time MI but also included
subjects with a recurrent diagnosis of or treatment for cor-
onary artery disease which could lead to more patients
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claimed significantly more ACEIs/ARBs than patients
without DM, i,e., 66.3% vs. 48.0%, in agreement with the
guideline recommendation, and the increased prevalence
of HF and renal disease in these patients (Table 1) [36].
The risk of lactic acidosis relating to concomitant use of
metformin in subjects with DM and renal impairment
may also have contributed to the underuse of ARB/ACEI
in patients with DM.
Statins
During the study period, the increase in the number of
patients claiming statins was greater than the increase in
the use of any of the other secondary prevention agents.
Indeed, 77.4% of patients claimed statins in 2003–2006,
and the increase in statin use was independent of DM
status. During the study period several landmark studies
and guidelines on primary and secondary prevention of
cardiovascular disease with statins were published which
probably contributed to the increased use [37-39]. Based
on current evidence all patients with MI and in particu-
lar patients with DM should receive statins [40]. Even a
higher fraction of patients with DM claiming statins may
therefore have been expected in the present study. The
proportion of women claiming statins was consistently
lower than the proportion of men, regardless of subject
age. Women have lower primary risk of coronary artery
disease than men, but in the post-MI population there
should be no differences in secondary prevention statin
use between genders. In particular, the elderly (≥70 years)
population claimed significantly fewer prescriptions for
statins, even though results of the Prospective Study of
Pravastatin in the Elderly at Risk (PROSPER) study pub-
lished in 2002 clearly showed a reduced risk of coronary
death and non-fatal MI in a population aged 70–82 years
with a history of (or risk factors for), vascular disease.
Combinations of secondary prevention drugs
A combination of secondary prevention pharmacother-
apies is frequently needed to optimize myocardial function
post MI and prevent subsequent adverse events [25,35].
Based on the marked survival advantages associated with
combination treatment of post MI patients the present
results are disappointing [41]. In our study only 32.1% of
patients with DM and 27.0% without DM claimed pre-
scriptions for ASA, ACEIs/ARBs, β –blockers, and statins
during the first 90 days post-MI. According to current evi-
dence DM patients should receive more aggressive post
MI therapy than patients without DM to reduce their in-
creased risk and the fact that they received less combin-
ation therapy, apart from combinations containing ACEIs/
ARBs, is disturbing. Our data essentially suggest a substan-
tial underuse of combinations of recommended secondary
prevention therapies after MI irrespective of DM status,not least since synergistic effects of co-administration
of such therapies are reasonably well established. For
example, in the Steno 2 trial published in 2003 [42] inten-
sive multifactorial interventions including ACEIs/ARBs,
β –blockers, and statins in patients with type 2 DM and
microalbuminuria reduced the risk of cardiovascular and
microvascular events by about 50%. The publication of this
study may have increased awareness of clinicians of the ef-
fectiveness of both primary and secondary preventive ther-
apies in patients with diabetes. Concerns about possible
drug interactions leading to inadequate initiation of therap-
ies and poor patient compliance in patients with chronic
disease may also contribute to drug underuse [43].
Numerous previous studies have examined the propor-
tion of hospitalized cardiac patients discharged with
secondary prevention medications. A meta-analysis of
data from 376,162 patients in 20 studies of primary and
secondary prevention (9 studies) assessing adherence
to aspirin, ACEIs, ARBs, β-blockers, calcium channel
blockers, thiazides, and statins found a mean general
adherence to secondary prevention therapies of 66%
[44]. A registry study of a 2008–2009 population cohort
in Spain of patients admitted with acute coronary syn-
drome found the proportions of drug adherence to be
69.9%, 45.4%, 43.3%, and 58.8%, for antiplatelet drugs,
ACEIs/ARBs β-blockers and statins, respectively. In that
study only 47.6% received 3 or more drugs and no asso-
ciation was found between low drug adherence and DM
[45]. Although we did not specifically examine drug ad-
herence but only used the correlate of claimed prescrip-
tions the use of ACEIs/ARBs, β-blockers and statins in
the late study period (2003–2006) in the present study is
consistent with these more recent results albeit that the
percentage of patients that used combinations of 3 or
more drugs (75,1%) in our study was markedly higher.
Methods to improve adherence to secondary prevention
therapies
Adherence is a key factor associated with the effective-
ness of all pharmacological therapies not least for
medications prescribed for chronic conditions like car-
diovascular diseases and DM. Medical adherence is a
complex issue and involves demographic, psychological,
and social factors, as well as factors related to the health
care provider, medical system, specific disease and treat-
ments. Improved adherence may be achieved by targeted
education of patients, involving patients in decisions re-
garding their treatments, changes of dosing regimens,
reduction of adverse effects, and improvements of access
to medication and medical consultations.
Limitations and strengths
The main study limitation is inherent in the observational
study design. The registers did not include information on
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tion, renal function, and contraindications for treatment.
Additionally, we did not know the number of patients
who initiated secondary prevention therapy during
hospitalization but did not tolerate treatment. Further-
more, the definition of DM was based on prescription
claims for GLDs. Therefore DM patients treated with diet
were identified as not having DM. The data collected in
this study origin only from Denmark and the results
should only be extrapolated to other countries with differ-
ent health care systems with caution. The use of secondary
prevention therapies after first MI according to the spe-
cific hospitals that patients were admitted to in Denmark
has been investigated previously and was found to vary
substantially [46]. In the present study, data from admis-
sions to a total of 82 hospitals were included and cluster-
ing of prescription claims, e.g., with patients discharged
from highly specialized cardiology clinics receiving more
evidence-based drugs than those discharged from commu-
nity hospitals, is likely to have influenced the results.
Therefore, our results apply to an average of Danish hospi-
tals and patients and cannot be extrapolated to represent
the performance status of any specific institution. The data
is now 5–15 years old but since the underlying fundamen-
tals, e.g., the free-of-charge health care system and well-
structured organisation of post-MI treatment in Denmark,
have not changed we sincerely believe that today’s situ-
ation in terms of suboptimal treatment of a considerable
number of patients is unlikely to be markedly different
from our 1997–2006 results. Indeed, in view of these
favourable features of the Danish health care system it is
likely that implementation of secondary prevention ther-
apies after MI is even worse in other countries. Therefore,
the overall message of our paper is likely to remain valid
and the implicit call for a focused effort to increase use of
evidence-based secondary prevention drugs is probably as
relevant today as in 2006.
The main strength of this study was the nationwide
consecutive patient registries, the contemporary data
collection, the large sample size comprising approxi-
mately 78,000 patients, and the use of pharmacy
dispensations and not prescriptions alone, which better
reflected true as opposed to intended drug use. Selection
bias arising from inclusion of only subgroups of patients
or patients from selected hospitals, medical centers, or
health care systems was avoided. Furthermore, the co-
hort comprised patients both in and out of the labor
market. In Denmark, a government-financed health care
system ensures practically equal access to health care for
all inhabitants.
Conclusions
In patients with first MI, the proportion of subjects who
claimed secondary prevention pharmacotherapies increasedsignificantly over time during 1997–2006. However, pa-
tients with DM claimed significantly less ASA and clopido-
grel and suboptimal use of drug combinations was found.
Moreover, women and elderly patients were less treated
with secondary prevention pharmacotherapy compared to
men and younger individuals, respectively. A focused effort
to increase use of evidence-based secondary prevention
drugs in post MI patients with and without DM is likely to
provide long-term benefit.
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